within Pharmacolibrary.Drugs.ATC.M;

model M01AG03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 1.2499999999999999e-06,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00014000000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.003,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01AG03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Flufenamic acid is a non-steroidal anti-inflammatory drug (NSAID) belonging to the fenamate class. It was previously used primarily for the treatment of inflammation and pain associated with conditions such as rheumatoid arthritis and osteoarthritis, but its current use is mostly historical due to the availability of safer alternatives.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adults based on literature for structurally related fenamates, as no comprehensive human PK models are published for flufenamic acid specifically.</p><h4>References</h4><ol><li><p>Alshehri, S, et al., &amp; Shakeel, F (2020). Flufenamic Acid-Loaded Self-Nanoemulsifying Drug Delivery System for Oral Delivery: From Formulation Statistical Optimization to Preclinical Anti-Inflammatory Assessment. <i>Journal of oleo science</i> 69(10) 1257–1271. DOI:<a href=\"https://doi.org/10.5650/jos.ess20070\">10.5650/jos.ess20070</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32908093/\">https://pubmed.ncbi.nlm.nih.gov/32908093</a></p></li><li><p>Lentjes, EG, &amp; van Ginneken, CA (1987). Pharmacokinetics of flufenamic acid in man. <i>International journal of clinical pharmacology, therapy, and toxicology</i> 25(4) 185–187. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3583467/\">https://pubmed.ncbi.nlm.nih.gov/3583467</a></p></li><li><p>Lee, Y, et al., &amp; Kim, YM (2011). Evaluation of dextran-flufenamic acid ester as a polymeric colon-specific prodrug of flufenamic acid, an anti-inflammatory drug, for chronotherapy. <i>Journal of drug targeting</i> 19(5) 336–343. DOI:<a href=\"https://doi.org/10.3109/1061186X.2010.499462\">10.3109/1061186X.2010.499462</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20615092/\">https://pubmed.ncbi.nlm.nih.gov/20615092</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01AG03;
